February 3, 2023
Medthority
NDA submitted to FDA for OX 124 a high-dose rescue medication for opioid overdose.- Orexo AB
Orexo AB (publ.), announces the submission of a New Drug Application (NDA) to the FDA for its lead ph... See more »
Active Biotech: Successful completion of the first stage of the phase IIa clinical trial of naptumomab in combination with docetaxel and the study is now enrolling into the second stage
Lund, June 1, 2022 - Active Biotech (NASDAQ STOCKHOLM: ACTI) and its partner NeoTX announce today the successful completion of the first stage of a Simon 2 stage phase IIa clinical trial of naptumomab...
Read full article »
February 3, 2023
PharmaTimes
Green light for AbbVie's Crohn's disease therapy Rinvoq
MHRA approval for Rinvoq which treats adults with moderate to severely active Crohn's Disease... See more »
February 3, 2023
Medthority
NDA submitted to FDA for OX 124 a high-dose rescue medication for opioid overdose.- Orexo AB
Orexo AB (publ.), announces the submission of a New Drug Application (NDA) to the FDA for its lead ph... See more »
February 3, 2023
PharmaTimes
Green light for AbbVie's Crohn's disease therapy Rinvoq
MHRA approval for Rinvoq which treats adults with moderate to severely active Crohn's Disease... See more »
President & CEO
Tomas Leanderson
Active Biotech focuses on developing pharmaceuticals products for immune defense.
Read more